share_log

基石藥業-B：截至二零二三年十二月三十一日止年度年度業績公告

CSTONE PHARMA-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023

香港交易所 ·  Mar 27 20:43
Summary by Futu AI
基石藥業-B（「本公司」）公布截至2023年12月31日止年度業績，總收入為人民幣463.8百萬元，較去年同期減少3.6%。其中，藥品銷售收入為人民幣336.7百萬元，授權費收入及特許權使用費收入同比增加8.6%，至人民幣127.1百萬元。研發開支較去年同期減少人民幣86.4百萬元，至人民幣527.8百萬元，主要由於里程碑費用及第三方合約成本以及僱員成本降低。行政開支亦減少至人民幣182.7百萬元。年內虧損為人民幣367.2百萬元，較去年減少59.3%。本公司於報告期間無派發股息，並無涉及任何重大訴訟或仲裁。
基石藥業-B（「本公司」）公布截至2023年12月31日止年度業績，總收入為人民幣463.8百萬元，較去年同期減少3.6%。其中，藥品銷售收入為人民幣336.7百萬元，授權費收入及特許權使用費收入同比增加8.6%，至人民幣127.1百萬元。研發開支較去年同期減少人民幣86.4百萬元，至人民幣527.8百萬元，主要由於里程碑費用及第三方合約成本以及僱員成本降低。行政開支亦減少至人民幣182.7百萬元。年內虧損為人民幣367.2百萬元，較去年減少59.3%。本公司於報告期間無派發股息，並無涉及任何重大訴訟或仲裁。
KEYSTONE PHARMACEUTICAL-B (THE “COMPANY”) ANNOUNCED ITS RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023 WITH A TOTAL REVENUE OF RMB463.8 MILLION, A DECREASE OF 3.6% COMPARED TO THE SAME PERIOD LAST YEAR. Among them, pharmaceutical sales revenue was RMB336.7 million, and license fee revenue and royalty fee revenue increased 8.6% year-over-year to RMB127.1 million. R&D expenses decreased by RMB86.4 million to RMB527.8 million from the same period last year, mainly due to lower milestone fees and third-party contract costs and employee costs. Administrative expenses were also reduced to RMB182.7 million. The loss for the year amounted to RMB367.2 million, a decrease of 59.3% from last year. The Company did not distribute dividends during the reporting period and was not involved in any significant litigation or arbitration.
KEYSTONE PHARMACEUTICAL-B (THE “COMPANY”) ANNOUNCED ITS RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023 WITH A TOTAL REVENUE OF RMB463.8 MILLION, A DECREASE OF 3.6% COMPARED TO THE SAME PERIOD LAST YEAR. Among them, pharmaceutical sales revenue was RMB336.7 million, and license fee revenue and royalty fee revenue increased 8.6% year-over-year to RMB127.1 million. R&D expenses decreased by RMB86.4 million to RMB527.8 million from the same period last year, mainly due to lower milestone fees and third-party contract costs and employee costs. Administrative expenses were also reduced to RMB182.7 million. The loss for the year amounted to RMB367.2 million, a decrease of 59.3% from last year. The Company did not distribute dividends during the reporting period and was not involved in any significant litigation or arbitration.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.